SMA Newsroom

Jan 18, 2023

Community statement regarding Biogen and Alcyone collaboration

From SMA Europe we would like to share that Biogen has announced a license and collaboration agreement with the US company, Alcyone Therapeutics, to evaluate further its investigational implantable device called ThecaFlex DRx™. 

ThecaFlex DRx offers an alternative means of nusinersen administration for people with SMA. 

For the full community statement, please see the attached document.